Literature DB >> 8722341

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT).

N Schmitz1, A Gratwohl, J M Goldman.   

Abstract

The indications and techniques employed for haematopoietic stem cell transplants performed in Europe differ substantially. The Accreditation Sub-Committee of the EBMT has consulted widely and has attempted to describe practice in Europe current in 1996 and in particular to define whether a particular procedure should be regarded as 'Routine' or whether it should be carried out preferably in the context of a Clinical Research Protocol or as part of a 'Developmental' pilot study. It is recognised that a classification of this kind must be imperfect and will require revision at frequent intervals.

Entities:  

Mesh:

Year:  1996        PMID: 8722341

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

Review 1.  [Transplantation of hematopoietic stem cells. II: Indications for transplantation of hematopoietic stem cells after myeloablative therapy].

Authors:  H Link; H J Kolb; W Ebell; D K Hossfeld; A Zander; D Niethammer; H Wandt; H Grosse-Wilde; U W Schaefer
Journal:  Med Klin (Munich)       Date:  1997-09-15

Review 2.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Authors:  A Sureda; P Bader; S Cesaro; P Dreger; R F Duarte; C Dufour; J H F Falkenburg; D Farge-Bancel; A Gennery; N Kröger; F Lanza; J C Marsh; A Nagler; C Peters; A Velardi; M Mohty; A Madrigal
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

3.  Hematopoietic stem cell transplantation activity and trends at a pediatric transplantation center in Turkey during 1998-2008.

Authors:  Volkan Hazar; Gülsün Karasu; Vedat Uygun; Mediha Akcan; Alphan Küpesiz; Akif Yeşilipek
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.